DocumentsDate added
ORIGINAL ARTICLE
S. Naveen1*,B. N. Lenka2,Alin Kumar Nayak1
1 Third Year PG Student, Department of General Surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
2 Assistant Professor, Department of General Surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
*Dr S. Naveen, Third Year PG Student,Department of General Surgery,Hi-Tech Medical College and Hospital,Bhubaneshwar, Odisha, India
Article citation: Naveen S, Lenka BN,Nayak AK. A clinical study of secondary haemorrhoids and its management. J Pharm Biomed Sci 2016;06(03): 238–240. Available at www.jpbms.info
ABSTRACT
Background Haemorrhoids are defined as the symptomatic enlargement and distal displacement of the normal anal cushions. The most common symptom of haemorrhoids is rectal bleeding associated with bowel movement. The abnormal dilatation and distortion of the vascular channel, together with destructive changes in the supporting connective tissue within the anal cushion, is a paramount finding of haemorrhoids. In most instances, haemorrhoids are treated conservatively using many methods such as lifestyle modification, fibre supplement, suppository, anti-inflammatory drugs and administration of venotonic drugs. Non-operative approaches include sclerotherapy and rubber band ligation. An operation is indicated when non-operative approaches have failed or complications have occurred. Several surgical approaches for treating haemorrhoids have been introduced including haemorrhoidectomy and stapled haemorrhoidopexy.
Materials and Methods Clinical study of secondary haemorrhoids and its management were collected from cases admitted in Hi-Tech Medical College and Hospital, Bhubaneswar,
Odisha, during the period from 1st January 2014 to 31st December 2015.
Results The study was conducted on 50 cases who were admitted in Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha with features of secondary haemorrhoids.
Conclusions In this study, we assess the common causes of secondary haemorrhoids and its management.
KEYWORDS secondary haemorrhoids, haemorrhoidal plexus, banding, haemorrhoidectomy (closed and stapled), bowel care, sitz bath
REFERENCES
1.Loder PB, Kamm MA, Nichold RJ, Philips RK. Hemorrhoids:pathology,pathophysiology and aetiology. Br J Surg. 1994;81:946–954.
2.Aigner F, Gruber H, Conrad F, Eder J, Wedel T, Zelger B, et al.Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. Int J Colorectal Dis. 2009;24:105–113.
3.Goldberg SM, Santhat N, David AR. Colon, rectum and anus in Schwartz principles of surgery, 6th ed. New York: Mchraw Hill;1994. p. 1192.
4.Thomson WH. The nature of haemorrhoids. Br J Surg. 1975;62(7):542–552.
5.Thaha MA, Campbell KL, Steele RJC. Non-operative treatment for haemorrhoidal disease. Cochrane Database Syst Rev. 2004;2.
6.MacRae HM, McLeod RS. Comparison of hemorrhoidal treatment modalities: a meta-analysis. Dis Colon Rectum. 1995;38:687–694.
7.Parks AG. The surgical treatment of hemorrhoids. Br J surg.1956;43:337–351.
8.Murie JA, Sim AJ, Mackenzie I. The importance of pain, pruritis and soiling as symptoms of hemorrhoids and their response to hemorrhoidectomy or rubber band ligation. Br J Surg. 1981;68:247–249.
9.Alonso-Coello P, Guyatt G, Heels-Ansdell D, Johanson JF, Lopez-Yarto M, Mills E, et al. Laxatives and topical treatments for hemorrhoids.Cochrane Database Syst Rev. 2005;2.
10.Harari D, Sarkarati M, Gurwitz JH, McGlinchey-Berroth G, Minaker KL. Constipation-related symptoms and bowel programme concerning individuals with spinal cord injury. Spinal Cord.1997;35:394–401.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Research article
Suresh V Dange1, Shrikrishna Subhash Shende2*,Balchandra T Rane3,Abhijeet V Tilak4,Moh anish U Vaidya2,Manasi V Limaye2
1 MBBS, MD Pharmacology, DNB Family Medicine, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri, Pune,411018, India
2 MBBS MD, Junior Resident, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
3 MBBS, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri,Pune, 411018, India
4 MBBS, MD Pharmacology, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
Address reprint requests to
*Dr. Shrikrishna Subhash Shende,
Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune 411018, India
Article citation: Dange SV, Shende SS,Rane BT, Tilak AV, Vaidya MU, Limaye MV. An observational study of the antidiabetic activity of berberine in newly diagnosed type 2 diabetes mellitus patients. J Pharm Biomed Sci 2016;06(03):230–233. Available at www.jpbms.info
Abstract:
Background Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to achieve glycemic targets. There is in fact a growing body of literature on plants used for the treatment of diabetes. In this respect, in the past few years, attempts were made to use natural plant products for the treatment of patients with diabetes.
Berberine is a commonly available as a nutraceutical and it is a potential candidate for diabetes. Methods and Results A total of 30 newly diagnosed type 2 diabetes mellitus patients
were included in the study after obtaining their informed written consent. They were divided into two groups (n = 15 each), receiving either metformin 500 mg/12 h or berberine 500 mg/12 h p.o. for 12 weeks. No other antidiabetic drugs were given. Therapeutic life style measures were common in both groups. Physical examination and estimation of laboratory parameters were done at baseline and after 12 weeks. Laboratory parameters estimated were fasting blood glucose level (FBG), post prandial blood glucose level (PPBG), glycated hemoglobin (GHb), lipid profile, serum alanine transferase and serum creatinine. Berberine treatment significantly reduced FBG, PPBG, GHb levels and there was significant improvement in lipid profile. The results were comparable to those with metformin.
Conclusion Berberine (500 mg twice daily) may be a useful antidiabetic drug.
KEYWORDS antidiabetic activity, berberine, type 2 diabetes mellitus.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Acknowledgement: The free samples of berberine (Berbeshine hydrochloride 500 mg) were provided by Akumentis Healthcare Ltd, Mumbai.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
REFERENCES
1.Ni YX. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi. 1988;8:711–713.
2.Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294:E148–E156.
3.Xie P, Zhou H, Gao Y. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]. Chin J Clin Healthcare. 2005;8:402–403.
4.Wei J, Wu J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine [article in Chinese]. Zhong Xi Yi Jie He Ganbing Za Zhi. 2004;14:334–336.
5.Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes. Metabolism. 2008;57(5):712–717.
6.Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Metaanalysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
7.Zhang Y, Li Y, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–2565.
8.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–2264.
9.Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism. 2007;56:405–412.
10.Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443.
11.Yin J, Chen M, Tang J, Li F, Zhou L, Yang Y, et al. Effects of berberine on glucose and lipid metabolism in animal experiment. Chin J Diabetes. 2004;12:215–218.
12.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes.2006;55:2256–2264.